KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsCash from RestructuringChange in CashDepreciation & Amortization (CF)Depreciation and DepletionDividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

West Pharmaceutical Services (WST) Free Cash Flow (2016 - 2025)

West Pharmaceutical Services' Free Cash Flow history spans 17 years, with the latest figure at $175.0 million for Q4 2025.

  • For Q4 2025, Free Cash Flow fell 57.23% year-over-year to $175.0 million; the TTM value through Dec 2025 reached $468.9 million, down 21.9%, while the annual FY2025 figure was $468.9 million, 21.9% down from the prior year.
  • Free Cash Flow for Q4 2025 was $175.0 million at West Pharmaceutical Services, up from $133.9 million in the prior quarter.
  • Across five years, Free Cash Flow topped out at $439.1 million in Q4 2023 and bottomed at -$50.4 million in Q3 2024.
  • The 5-year median for Free Cash Flow is $104.4 million (2022), against an average of $140.7 million.
  • The largest annual shift saw Free Cash Flow crashed 137.53% in 2024 before it soared 365.67% in 2025.
  • A 5-year view of Free Cash Flow shows it stood at $84.3 million in 2021, then skyrocketed by 359.43% to $387.3 million in 2022, then rose by 13.37% to $439.1 million in 2023, then fell by 6.81% to $409.2 million in 2024, then tumbled by 57.23% to $175.0 million in 2025.
  • Per Business Quant, the three most recent readings for WST's Free Cash Flow are $175.0 million (Q4 2025), $133.9 million (Q3 2025), and $101.9 million (Q2 2025).